搜索结果：Journal of pharmaceutical sciences

In the human use experience study of TCM, researchers may intentionally or unintentionally ignore the interests of patients due to their own interests or the interests of medical institutions. Conflict of interest is a common existing situation in the human use experience study, and early and thorough identification and management of conflicts of interest are necessary to ensure studies' neutrality. This paper systematically discussed the basic concept of conflicts of interest and introduced the classification of clinical studies and management regulations for conflicts of interest in China and abroad. By elaborating on the connotation of human use experience and interpreting related laws, regulations, and guiding principles, it was proposed that the first phase of the human use experience study should be managed with reference to IIT of TCM, and the second phase should be implemented in accordance with GCP requirements. Based on a comprehensive analysis of the attributes of the human use experience study and the characteristics of conflicts of interest, the Professional Committee of Clinical Evaluation of TCM of the Chinese Pharmaceutical Association has formulated the management guidelines for conflicts of interest, covering nine aspects: scope of application, stakeholders, disclosure of conflicts of interest, research proposal review, ethics committee review, research quality management, supervision for conflicts of interest, translation of research achievements, and management for conflicts of interest, thereby ensuring the standardized conduct of the human use experience study.

In the last decades there has been a growing interest in pregnant and breastfeeding patient's health and growing attention to the effects of drugs and chemicals during pregnancy and lactation. For this reason, many Teratology Information Services (TIS) have been established in Europe, providing information on known reproductive risks, conducting epidemiologic research and pharmacovigilance on drug-induced congenital malformations and cooperating within the European Network of Teratology Information Services (ENTIS). The Poison Control Centres (PCC) too may be contacted by patients for the use of drugs in pregnancy and lactation, and they can provide such advise with similar or lower confidence in comparison to the TIS. The objective of this study is to identify among the PCC members of the European Association of Poison Centres and Clinical Toxicologists (EAPCCT) those that provide information or intend to provide better information on the use of drugs during pregnancy and lactation to the patients or to health professionals, with a perspective of expanding the collaboration between these two associations by offering training through webinars or other type of scientific information. We invited the PCC in Europe to participate in a survey asking if and how they provide information about medicines during pregnancy and lactation. A second survey was carried out among the ENTIS members in order to assess the overall patients need for such type of advice. Fifty-six PCC from 28 European countries received the invitation to participate in the survey. A total of 93% from 26 countries responded within 3 months after the first request. Sixty-two per cent of the PCC provide information on the use of drugs in pregnancy and lactation in the order of a 1,500-2,000 calls/year, while only 19% of the PCC include a TIS. Overall, 35% of the PCC were interested in expanding their knowledge in the teratology field. All 26 TIS from 16 countries participated in the survey: they provide information for more than 118,000 cases per year. The collaboration between the PCC and TIS is potentially advantageous in order to share information and to provide a training to the clinical toxicologists in the field of clinical teratology in countries where there isn't a TIS, especially in the Eastern Europe where the TIS are almost absent. This will in turn provide a benefit to the health care professionals who may lack an evidence-based knowledge on medication safety in pregnancy.

Healthcare quality is an important dimension of health system performance and a key criterion for evaluating the effectiveness of China's deepening healthcare system reform. This study treats the National Comprehensive Medical Reform pilot as a quasi-natural experiment to examine its impact on healthcare quality and further analyzes the potential mechanism of pharmaceutical pricing reform. Based on panel data from 31 provinces in China from 2012 to 2020, combined with data on medical malpractice liability disputes from China Judgments Online, this study employs a multi-period difference-in-differences model to identify the policy effect of the National Comprehensive Medical Reform pilot. Healthcare quality is measured by the incidence of medical malpractice liability disputes and inpatient mortality, and the mechanism of pharmaceutical pricing reform is analyzed through changes in the structure of medical expenditures. The study finds that the National Comprehensive Medical Reform pilot significantly reduced the incidence of medical malpractice liability disputes and inpatient mortality, indicating that the reform helped improve healthcare quality. Mechanism analysis shows that the reform significantly reduced drug expenditure per outpatient visit and per inpatient admission, lowered the share of drug expenditure, and increased the share of medical service fees. These findings suggest that the National Comprehensive Medical Reform may have improved healthcare quality by reducing hospitals' dependence on drug-related revenue, increasing the relative importance of service-based income, and reshaping hospital revenue structures and provider incentive mechanisms. However, the share of examination fees increased significantly, indicating the possible presence of substitute revenue-seeking incentives and associated quality risks during the reform process. The National Comprehensive Medical Reform pilot had a positive effect on improving healthcare quality, and its mechanism may be related to hospital revenue restructuring and the optimization of healthcare service incentives induced by pharmaceutical pricing reform. Future reforms should further strengthen coordination among medical care, medical insurance, and pharmaceuticals, continue to optimize medical service pricing and compensation mechanisms, and curb substitute revenue-seeking behavior, so as to provide a more stable and sustainable institutional foundation for the continuous improvement of healthcare quality.

Pharmaceutical and cosmetic preservatives play a critical role in inhibiting microbial contamination, preventing chemical degradation, and maintaining product efficacy and safety throughout the shelf life. Given their functional importance, comparable to that of active pharmaceutical ingredients, it is essential to monitor their quality using advanced analytical techniques. Among the most commonly employed seven varieties of preservatives in industry are 2,4-dihydroxybenzoic acid, 4-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, benzyl alcohol, benzaldehyde, phenol, sodium benzoate, methylparaben, and propylparaben, either individually or in combination. The present study focuses on the development and validation of a stability-indicating, reverse-phase high-performance liquid chromatography method for simultaneous quantification of these seven preservatives and their impurities, benzaldehyde and phenol, a total of nine components. The method demonstrates high selectivity, sensitivity, accuracy, and precision, and meets the validation criteria outlined in International Council for Harmonization (ICH) guidelines. Optimal chromatographic resolution was achieved using a Phenomenex Luna C18 column, dual-wavelength UV detection at 254 and 230 nm, and a gradient mobile phase consisting of 0.1% orthophosphoric acid and acetonitrile. The method was established within a range of 1.5-45.0μg/mL concentration for all components. The validated method is suitable for routine quality control testing across various pharmaceutical and cosmetic formulations.

Since the onset of the 2023 Israel-Gaza war, the healthcare system in the Gaza Strip has nearly collapsed. More than 70,937 casualties and 171,192 injuries have been reported, yet limited data exist on injury types and outcomes. Critical care services are essential during conflicts. This study aimed to determine causes of intensive care unit (ICU) admissions, associated injuries, complications, and outcomes in the Gaza Strip. We conducted a prospective cohort study of all adult and pediatric patients admitted to the ICUs at European Gaza Hospital and Shuhada Al-Aqsa Hospital between May 29 and June 30, 2024. Outcomes of interest were causes of admission, survival, types of complications, and length of stay. A total of 115 patients were admitted. Median age was 27 years (interquartile range 18-38), including 30 pediatric patients (26%). Thirty-five patients were female (30%). Trauma with or without burns accounted for 75 admissions (65%), while 27 (23.5%) had medical causes. Among trauma patients, 56 (75%) were from explosive injuries; traumatic brain injury was most common (30/75, 40%), including 10 of 21 pediatric trauma patients (47.6%). During ICU stay, 12 patients developed sepsis (10.6%), 10 developed septic shock (8.8%), and 12 developed multiorgan dysfunction (10.6%). Of 112 patients with known disposition, 64 were discharged and 48 died (43%). Median ICU survival was 6 days (95% confidence interval 5-17), and 17 days for pediatric patients (95% confidence interval 5-not calculable). Severe traumatic brain injury (33%) was the leading cause of death, followed by septic shock (22%). The high burden of trauma, complications, and mortality reflects the critical collapse of Gaza's healthcare system. Women and children represented a substantial proportion of ICU patients, highlighting civilian vulnerability. Urgent international medical intervention, humanitarian support, and a permanent ceasefire are essential to prevent continued loss of life.

Remdesivir (REM), a nucleoside analogue that has been approved for SARS-CoV-2 treatment, is poorly soluble in water and is currently administered intravenously formulated with sulfobutylether-β-cyclodextrin (SBECD) to facilitate solubilization. The major drawback associated with SBECD in the clinical setting is its high excipient load in the formulation leading to potential risk of renal accumulation, especially in patients with pre-existing impaired renal function and need of specialized staff trained in IV administration. The objective of this study was to investigate acid-functionalized poly(jasmine lactone) (PJL) based copolymers as potential alternatives to β-cyclodextrin based formulations for subcutaneous delivery of REM. PJL was selected because of its hydrophobic backbone and tunable functional group, making it more suited for hydrophobic interaction with REM. REM loaded PJL micelles were prepared utilizing nanoprecipitation technique and characterized for drug content, particle size, stability, in vitro release of REM, antiviral efficacy against human coronavirus HCoV-229E, pharmacokinetic profile and biodistribution in CD-1 mice. The thus prepared REM micelles exhibited a uniform nanoparticulate size with high loading efficiency of 96%, significant physicochemical stability at 4 °C up to 12 months and sustained REM release at pH 6.8 (≈ 100% in 24 h). The micelles demonstrated ≈ 100% inhibition against human coronavirus HCoV-229E, equivalent to the marketed formulation Jubi-R™ used for benchmarking. In vivo studies indicate increased systemic exposure and peak concentration of 217 ng/mL compared to 134 ng/mL after subcutaneous administration compared to marketed IV administration of micelles. The in vivo results also indicated an accumulation of the REM metabolite (GS-441524) in the lungs, demonstrating more targeted tissue distribution and production of active metabolites in vivo. Overall, these results provide evidence that PJL mediated micellar delivery of REM resulted in successful solubilization and delivery through a less invasive means of administration representing a promising biocompatible platform for delivering antiviral drug with improved systemic exposure.

The generation of N-nitrosamine compounds (NOCs) in drugs presents a critical regulatory challenge owing to their potential mutagenicity and exceptionally strict acceptable intake limits required for patient safety. These impurities arise primarily from the reaction between amine-containing active pharmaceutical ingredients and trace amounts of nitrosating agents (reactive NOx), which contribute to N-nitrosation. Reactive NOx species are frequently found in pharmaceutical excipients. Therefore, efficiently reducing reactive NOx is essential for robust management of the risk posed by NOCs. In this study, we employed ultraviolet (UV) irradiation of excipients as a novel preemptive strategy to reduce reactive NOx levels. Desloratadine was used as a secondary amine model to evaluate the generation of N-nitrosamine in physical mixtures with various excipients. The excipients were exposed to different UV wavelengths (248, 313, and 365 nm), and N-nitrosodesloratadine (NDLRT) generation was quantified after storage under stress conditions. We found that 365 nm UV irradiation was the most effective in reducing reactive NOx under all conditions. In a formulation study, 365 nm UV irradiation successfully reduced NDLRT generation in the tablet by 54-68% compared with the control. Overall, the novel strategy described herein should be useful for reducing NOCs without affecting the quality of drugs.

The Sicilian Black pig is a well-adapted autochthonous breed, yet its susceptibility to respiratory disease remains poorly defined due to limited data on pathogen circulation and lesion patterns in extensive production systems. This study characterised the pathological features of Porcine Respiratory Disease Complex (PRDC) in this breed by examining lungs and tracheobronchial lymph nodes from 59 animals through pathological assessment, molecular detection of major respiratory pathogens, and evaluation of crystalline particulates using scanning electron microscopy coupled with energy-dispersive X-ray analysis to characterise infectious and environmental contributors. Gross examination revealed multifocal cranioventral bronchopneumonia in 35/59 pigs (59.32%) and diffuse interstitial pneumonia in 18/59 pigs (30.51%). Molecular testing identified Mycoplasma hyopneumoniae (M. hyopneumoniae) as the most frequent pathogen (17/47; 36.17%), followed by porcine circovirus type 2 (PCV2; 10/47; 21.28%) and Pasteurella multocida (6/47; 12.77%), with co-infections consistently involving M. hyopneumoniae. The presence of pathogen DNA was correlated with increased severity of lesions as well as the presence of fibrosis and hyperplasia of the BALT. Histological evidence of Metastrongylus spp. lungworms was identified in 7/35 pigs (20%) with bronchopneumonia. Silicate crystals consistent with pulmonary silicosis were detected in 10/59 lungs (17.0%), indicating substantial exposure to silicate-rich dust in outdoor environments. However, silicosis was not related to the presence of specific respiratory pathogens. Overall, these findings demonstrate that respiratory disease in Sicilian Black pigs is multifactorial, arising from the combined influence of bacterial, viral, parasitic, and environmental components. The concurrent detection of M. hyopneumoniae, PCV2, secondary bacterial agents, lungworm infestation, and silicate particulates supports an integrated PRDC model in this native breed. These results highlight the need for a multifaceted control strategy, including improved diagnostics, targeted management, immunoprophylaxis, helminth control, and mitigation of silicate-rich dust to reduce the impact of PRDC in extensive production systems.

Conjunctivitis is the most prevalent ocular disorder and characterized by irritation, swelling and inflammation of the conjunctiva. Fluoroquinolones are the most promising classes of antibiotics and among them; ciprofloxacin (CFX) is used to treat conjunctivitis. To provide a controlled-release approach for extended antibacterial action, CFX-loaded thiolated gum ghatti (TGG) nanoparticles were developed to overcome the drawbacks of traditional eye medications (rapid elimination, low bioavailability). Gum ghatti (GG) was thiolated with 3-mercaptopropionic acid (3-MPA) to enhance the mucoadhesion. The nanoprecipitation technique was applied to produce nanoparticles of TGG loaded with CFX. Particle size, zeta potential, FTIR, DSC, TGA, and XRD were employed to characterize GG, TGG, and nanoparticles. Permeation, mucoadhesion, ocular irritation and pharmacokinetics were performed. TGG and nanoparticles contained 0.09 and 0.13 mmoL of thiol groups/mg of polymer, respectively. Nanoparticles showed a diameter of <&#x2009;200&#xa0;nm and PDI of <&#x2009;0.3, and showed improved CFX penetration by 80% compared to pure CFX. Nanoparticulate formulation showed no ocular irritation and sustained release of CFX with improved pharmacokinetic parameters. Thiolation is responsible for the improved mucoadhesion of TGG (1-fold) and nanoparticle (2-fold) compared to GG, making it suitable for creating eye formulations for the treatment of bacterial infections.

IDH305 was developed as an orally available, mutant-selective, allosteric inhibitor of isocitrate dehydrogenase (IDH)1 for cancer treatment. It is a substrate, time-dependent inhibitor, and inducer of cytochrome P450 (CYP)3A4. As part of model-informed drug development (MIDD) of IDH305, two prospective physiologically based pharmacokinetic (PBPK) models were developed and CYP3A4 humanized mouse model was utilized to inform the first-in-human (FIH) study, where patients with advanced malignancies were to take IDH305 twice daily. The objectives are addressing whether food could be given with IDH305 and whether accumulation or reduction of PK exposure would occur follow repeat dosing. The absorption PBPK model predicted no food effect of light meals at 300 mg dose and informed the FIH study to allow dosing with light meals in cancer patients. The metabolic PBPK model, along with CYP3A4 humanized mouse studies, evaluated the interplay of CYP3A4 inhibition and induction and predicted a net outcome of modest accumulation (accumulation ratio 1.5-1.9). Both the predicted food effect and accumulation ratio were consistent with the observed data in the FIH study. This integrative translational approach informed clinical development of IDH305 and can be used to support MIDD of molecules with complex metabolic properties in oncology drug development.

This research presents the development of a novel pH-sensitive PEG (HEMA-co-AA) graft copolymer hydrogel designed to provide controlled and protective delivery of acid-labile drugs, specifically Rabeprazole sodium. The hydrogel was synthesized using polyethylene glycol (PEG), 2-hydroxyethyl methacrylate (HEMA), acrylic acid (AA), with N,N'-methylene bisacrylamide (MBA) as a cross-linker and potassium persulfate (KPS) as an initiator. The hydrogel's structural integrity and formation were confirmed through Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), differential scanning calorimetry (DSC), and swelling studies. It is noteworthy that the hydrogel exhibits a different pH-dependent swelling behaviour, which expands under alkaline conditions and maintains its compact structure under acidic conditions. The content of acrylic acid contributed to the high-water retention and the swelling profile indicated that the product was suitable for the specific release of the drug at the site. The in-vitro release of rabeprazole sodium at acidic pH is very low, thus protecting rabeprazole sodium from premature degradation in the stomach; however, controlled release of rabeprazole sodium was achieved at intestinal pH via a non-Fickian diffusion mechanism (Korsmeyer-Peppas n = 0.40-0.62, Higuchi R&#xb2; = 0.991-0.996) over 12 h. Moreover, in-vivo acute toxicity studies indicated that the hydrogel is highly biocompatible, suggesting it is safe for use in future therapeutic applications. Overall, the PEG (HEMA-co-AA) hydrogel represents a versatile vehicle for the controlled and local administration of acid-labile pharmaceuticals, thereby promoting increased therapeutic efficacy.

Biomarkers play a crucial role in disease diagnosis and therapeutic monitoring, necessitating the development of reliable and robust analytical methods. Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely employed for biomarker analysis due to its versatility, sensitivity and reproducibility. However, conventional method development approaches are based on trial-and-error strategies, leading to limited robustness and poor reproducibility. The Analytical Quality by Design (AQbD) framework has emerged as a systematic approach to overcome these limitations. This review critically evaluates reported RP-HPLC methods for biomarker analysis in the context of AQbD principles. Key elements, including Analytical Target Profile (ATP), Critical Quality Attributes (CQAs), Critical Method Parameters (CMPs), risk assessment, Design of Experiments (DoE) and Method Operable Design Region (MODR), are discussed. Analysis of selected studies indicates that most lack comprehensive AQbD implementation, particularly in terms of multivariate optimization, structured risk assessment and design space establishment. Common limitations such as coelution, sensitivity and inadequate robustness are highlighted, along with AQbD-based strategies to address these challenges. Additionally, recent trends, including the integration of machine learning and the adoption of Green and White Analytical Chemistry principles, are discussed to promote sustainable method development. Overall, AQbD offers a robust framework for improving analytical performance for biomarker analysis.

It is essential to control epidemic diseases and adopt an optimal strategy when an epidemic occurs. In this research, a myopic model is presented. In this regard, an epidemic model is presented considering social challenges such as vaccine acceptance, quarantine of infected individuals, and regional quarantine. The vaccine allocation model was constructed to incorporate specific outputs from the epidemiological model, including (i) the weight of each cluster within each region, (ii) the vaccine demand of each cluster in each region, (iii) the relative infectiousness of region g, and (iv) the relative susceptibility of region g. By integrating these parameters, the allocation model determines equitable distribution strategies that aim to reduce the effective reproduction number. The model is run based on the data provided in similar articles, and its results are analyzed. By incorporating economic factors, like the costs of interventions, along with social factors such as individuals' willingness to get vaccinated, this model allows for an exploration of various aspects related to the fair allocation of vaccines. The rationality of the model's outcomes, supported by expert validation and reinforced through sensitivity analysis, underscores its accuracy and reliability.

Promethazine hydrochloride, a first-generation H1 receptor blocking agent, possesses antimuscarinic, sedative, and serotonin antagonistic properties. It is widely used as an antiemetic for treating nausea and vomiting caused by motion sickness, vertigo, postoperative and drug-induced vomiting, and Meniere's disease. Although extensively absorbed after oral administration, it undergoes significant first-pass metabolism, resulting in poor bioavailability of about 25 %. To overcome this limitation and improve patient compliance, the nasal route was explored owing to its high vascularity, large surface area, and absence of first-pass metabolism. The major drawback of nasal delivery, mucociliary clearance (MCC), was addressed by formulating a thermosensitive mucoadhesive in situ hydrogel, enhancing residence time and bioavailability. The study aimed to evaluate the safety, stability, and bioavailability of the intranasal in situ hydrogel of promethazine hydrochloride. Safety was assessed using freshly excised sheep nasal mucosa, while accelerated stability studies confirmed formulation stability. In vivo studies were performed using New Zealand White rabbits, and pharmacokinetic parameters were calculated by the trapezoidal rule using a validated HPLC method. The optimized formulation exhibited a Cmax of 296.18 ng/ml, Tmax of 1 hour, and bioavailability of 36.42 %, which is 62.58 % higher than after oral administration, indicating intranasal in situ hydrogel as a promising approach for enhancing bioavailability of antiemetic drugs.

An accurate and green RP-HPLC stability indicating method has been developed for estimation of Imeglimin with an AQbD approach. Method optimization was done based on Box-Behnken design by changing factors like mobile phase, pH, and flow rate for optimum resolution and retention time. Lean Six Sigma (DMAIC) and statistical process control techniques ensured the consistency of the method. Water-methanol in the ratio of 65:35 (v/v) adjusted to pH&#x2009;4.0 was used as the mobile phase at a flow rate of 0.8&#x2009;mL/min, having an approximate retention time of 3.7&#x2009;min. Method validation was performed as per the ICH guidelines, and the method exhibited a high correlation coefficient (R2&#x2009;=&#x2009;0.9994), low %RSD (<&#x2009;2%), and good accuracy (99.45%-100.35%). LOD and LOQ were found to be 1.04 and 3.15&#x2009;&#x3bc;g/mL, respectively. The results of forced degradation experiments showed significant degradation in the presence of alkaline, oxidative, and thermal stress conditions, whereas Imeglimin remained stable under photolytic stress conditions. HR-MS and FTIR studies indicated that N-dealkylation and N-demethylation were possible degradation pathways. The greenness assessment of the developed method was carried out using AGREE, GAPI, BAGI, and CLICK indices.

This study employed an ensemble species distribution model Biomod2 integrated with ArcGIS spatial analysis and utilized climate, soil, and human footprint data to predict the potential suitable habitats for Ophiopogon japonicus under various scenarios and to assess the key drivers governing its distribution. RESULTS:: revealed that mean diurnal temperature range, temperature seasonality, and human footprint were the primary factors determining its distribution. When anthropogenic disturbances were excluded, the area of highly suitable habitats expanded significantly, extending notably into regions such as Guizhou, Chongqing, and Jiangsu. Under a low carbon emission scenario, the suitable habitat area showed a trend of gradual increase followed by stabilization. In contrast, under a high emission scenario, it contracted substantially and exhibited increased spatial fragmentation. In short, human activities and climate change had a significant impact on the suitable producing areas for O. japonicus. The findings provided an important scientific basis for the conservation and utilization of key producing areas, the long-term preservation of germplasm resources, and the sustainable development of the O. japonicus industry. Furthermore, this study demonstrated that the ensemble modeling approach enhanced the scientific validity and robustness of producing area predictions, offering valuable insights for optimizing future habitat planning and adaptive management strategies of O. japonicus.

A method developed and validated for the assay of fenofibrate in tablet dosage form by isocratic RP-UHPLC-UV technique has been rapid and precise. The material was chromatographed on Shim-pack Velox C18 column (50&#x2009;&#xd7;&#x2009;2.1&#x2009;mm, 1.8&#x2009;&#x3bc;m) at 40&#xb0;C with isocratic mobile phase: acidified water/acetonitrile (60:40, v/v) at 0.4&#x2009;mL/min and at a detection wavelength of 286&#x2009;nm. The total run time was 6.0&#x2009;min and fenofibrate eluted at ~2.4&#x2009;min. The method was linear over 10-90&#x2009;&#x3bc;g/mL (r2&#x2009;=&#x2009;0.9995) with LOD/LOQ of 0.239/0.673&#x2009;&#x3bc;g/mL. The precision and accuracy (RSD less than 2% and 96%-100% recovery) comply with ICH Q2(R1) requirements both intra-day and inter-day. The present UHPLC method significantly shortens the analysis time and solvent consumption compared with the reported HPLC methods (typical run time >&#x2009;8-20&#x2009;min) without compromising of the sensitivity, which allows to use the present method for routine quality control of fenofibrate tablets.

To evaluate construct validity and responsiveness of the health-related quality of life (HRQoL) instrument EQ-5D-3L (index, dimensions) and EQ VAS among patients with psoriatic arthritis (PsA). This retrospective, register-based study utilised data from the Swedish Rheumatology Quality Register. Known-groups validity was assessed by comparing EQ-5D-3L and EQ VAS results across groups with varying levels of physical function or disease activity. Convergent validity was assessed through correlations with comparator instruments. Responsiveness was assessed by analysing correlations between changes in EQ-5D-3L, EQ VAS, and comparator instruments, as well as by assessing the ability to discriminate between patients who improved and those who did not, using the area under the receiver operating characteristic curve (AUC). To confirm construct validity or responsiveness,&#x2009;&#x2265;&#x2009;75% of hypotheses had to be supported. The study included 13,105 patients with PsA. EQ-5D-3L and EQ VAS demonstrated moderate to strong correlations with comparator instruments and found expected differences between groups with varying physical function or disease activity. Over 75% of the hypotheses related to construct validity were supported. Regarding responsiveness, several hypotheses for the EQ-5D-3L were not supported, and none of the AUC-related hypotheses for EQ VAS were supported. Overall, less than 75% of the hypotheses related to responsiveness for EQ-5D-3L and EQ VAS were supported. The results from this observational study support construct validity of EQ-5D-3L and EQ VAS among patients with PsA. However, responsiveness was not supported for the EQ-5D-3L dimensions which suggests that the EQ-5D-3L may not fully capture changes in HRQoL from interventions impacting other dimensions than pain/discomfort.

The combination of avutometinib, a dual RAF/MEK inhibitor targeting the MAPK pathway, and defactinib, a selective focal adhesion kinase (FAK) inhibitor, represents a recently approved combination therapy for patients with KRAS-mutated or KRIS-mutated recurrent LGSOC (low-grade serous ovarian cancers). A comprehensive review of the literature indicates that although clinical studies have demonstrated the therapeutic potential of this combination, limited information is available regarding simultaneous quantification in biological matrices. Therefore, the present study mainly focused on a rapid selective and specific LC-MS/MS method that was developed and fully validated for the estimation of avutometinib and defactinib in rat plasma. Chromatographic separation was achieved using a reverse phase Kinetex PS C18 2.1*50&#x2009;mm, 3.5 um, 100A&#xb0; column under gradient elution with 0.1% formic acid in water and 0.1% formic acid in acetonitrile as mobile phases. The flow rate was 0.6&#x2009;mL/min, and glyburide was employed as the internal standard (IS). Mass spectrometric detection was performed using positive electrospray ionization mode and multiple reaction monitoring was applied for the quantitative analysis. Protein precipitation with acetonitrile was used for sample preparation. The method demonstrated an excellent linearity range of 1&#x2009;ng/mL to 1000&#x2009;ng/mL for both analytes (r2&#x2009;>&#x2009;0.99). Intraday and interday accuracy and precision were observed to be within the acceptable regulatory limits for all quality control levels. Considering the limited availability of validated bioanalytical methods for this drug combination, the present work provides a robust and sensitive LC-MS/MS approach for the simultaneous quantification of avutometinib and defactinib. This validated method was successfully applied to a rat pharmacokinetic study following oral administration of both analytes.